Lactate dehydrogenase isoenzyme 1 in testis cancer. 1987

F E von Eyben, and O Blaabjerg, and P H Petersen, and M Hørder, and H V Nielsen, and S K Andersen, and E Parlev

UI MeSH Term Description Entries
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D007770 L-Lactate Dehydrogenase A tetrameric enzyme that, along with the coenzyme NAD+, catalyzes the interconversion of LACTATE and PYRUVATE. In vertebrates, genes for three different subunits (LDH-A, LDH-B and LDH-C) exist. Lactate Dehydrogenase,Dehydrogenase, L-Lactate,Dehydrogenase, Lactate,L Lactate Dehydrogenase
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D004407 Dysgerminoma A malignant ovarian neoplasm, thought to be derived from primordial germ cells of the sexually undifferentiated embryonic gonad. It is the counterpart of the classical seminoma of the testis, to which it is both grossly and histologically identical. Dysgerminomas comprise 16% of all germ cell tumors but are rare before the age of 10, although nearly 50% occur before the age of 20. They are generally considered of low-grade malignancy but may spread if the tumor extends through its capsule and involves lymph nodes or blood vessels. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1646) Disgerminoma,Disgerminomas,Dysgerminomas
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013736 Testicular Neoplasms Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms. Cancer of Testis,Cancer of the Testes,Testicular Cancer,Testicular Neoplasm,Testicular Tumor,Testis Cancer,Cancer of the Testis,Neoplasms, Testicular,Neoplasms, Testis,Testicular Tumors,Testis Neoplasms,Tumor of Rete Testis,Cancer, Testicular,Cancer, Testis,Cancers, Testicular,Cancers, Testis,Neoplasm, Testicular,Neoplasm, Testis,Rete Testis Tumor,Rete Testis Tumors,Testicular Cancers,Testis Cancers,Testis Neoplasm,Testis Tumor, Rete,Testis Tumors, Rete,Tumor, Testicular,Tumors, Testicular
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers

Related Publications

F E von Eyben, and O Blaabjerg, and P H Petersen, and M Hørder, and H V Nielsen, and S K Andersen, and E Parlev
March 1984, American journal of clinical pathology,
F E von Eyben, and O Blaabjerg, and P H Petersen, and M Hørder, and H V Nielsen, and S K Andersen, and E Parlev
January 1984, Clinical chemistry,
F E von Eyben, and O Blaabjerg, and P H Petersen, and M Hørder, and H V Nielsen, and S K Andersen, and E Parlev
August 1982, American journal of clinical pathology,
F E von Eyben, and O Blaabjerg, and P H Petersen, and M Hørder, and H V Nielsen, and S K Andersen, and E Parlev
June 1985, Clinical chemistry,
F E von Eyben, and O Blaabjerg, and P H Petersen, and M Hørder, and H V Nielsen, and S K Andersen, and E Parlev
July 1990, Clinical chemistry,
F E von Eyben, and O Blaabjerg, and P H Petersen, and M Hørder, and H V Nielsen, and S K Andersen, and E Parlev
October 1974, Rinsho byori. The Japanese journal of clinical pathology,
F E von Eyben, and O Blaabjerg, and P H Petersen, and M Hørder, and H V Nielsen, and S K Andersen, and E Parlev
October 1996, Clinical chemistry,
F E von Eyben, and O Blaabjerg, and P H Petersen, and M Hørder, and H V Nielsen, and S K Andersen, and E Parlev
April 1990, Clinical chemistry,
F E von Eyben, and O Blaabjerg, and P H Petersen, and M Hørder, and H V Nielsen, and S K Andersen, and E Parlev
August 1984, Clinical chemistry,
F E von Eyben, and O Blaabjerg, and P H Petersen, and M Hørder, and H V Nielsen, and S K Andersen, and E Parlev
November 1981, Ugeskrift for laeger,
Copied contents to your clipboard!